



ASX ANNOUNCEMENT

3 December 2020

Share Purchase Plan Announced

CardieX Limited (ASX: CDX) (CardieX, the Company) advises that the Company will offer eligible shareholders and opportunity to apply for up to \$30,000 of new shares in the Company under a Share Purchase Plan (the SPP).

CardieX is targeting to raise \$1.0 million under the SPP, and the Company retains its absolute discretion to close the SPP early, scale back applications, or accept an amount above or below the \$1.0 million target depending on the level of demand received.

Any scale back will be conducted on a pro-rata basis to either the size of each applicant's existing security holdings or the number of securities each applicant has applied for. The Company is currently expecting to close the SPP on Thursday, 31 December 2020.

The SPP booklet which has full details of the SPP will be sent to all shareholders either by email or by post. Shareholders can also access the SPP booklet and make an application online at cardiex.com/2020SPP.

The Company intends for the funds raised under the SPP to be used primarily for working capital purposes and investment into the expansion of product and market development initiatives as previously announced.

Importantly, we reiterate previous announcements that we currently retain sufficient cash reserves for the execution of our new product development strategy and business operations. The SPP is solely to enable our retail shareholders to have the opportunity to participate in the next growth phase of the Company at price levels that may not otherwise be available to them. The Directors have been mindful of retail shareholders in the past not being able to directly participate in capital raises and this is an opportunity for them to do so directly.

An indicative timetable for the completion of the SPP is as follows:

Event	Indicative Date
Record Date	Tuesday, 2 December 2020
Announcement of SPP	Wednesday, 3 December 2020
SPP Opens and Documentation Sent	Monday, 7 December 2020
SPP Closes	Thursday, 31 December 2020
Announcement of Demand and Scale Back	Wednesday, 6 January 2021



Allotment and Issue of SPP Shares	Tuesday, 12 January 2021
ASX Quotation of SPP Shares	Wednesday, 13 January 2021
Dispatch of Shareholder Statements for SPP Participants	Friday, 15 January 2021
Indicative timetable and is subject to change without notice. The Company reserves the right to vary the dates above, subject to any regulatory or statutory provisions that may apply.	

If Shareholders have any queries on how to participate including on how to access the application, please call +61 2 8296 0000 or consult your financial or other professional adviser.

Authorised for release by the Board of Directors, and released by Jarrod White

For more information please contact:

Investor Relations

Rod Hinchcliffe

rod.hinchcliffe@mcpartners.com.au

Media Relations

Melissa Hamilton

melissa.hamilton@mcpartners.com

About CardieX

CardieX is a global health technology company that focuses on hypertension, cardiovascular disease, and other vascular health disorders. The company's ATCOR division is the world leader in medical devices for measuring arterial stiffness and central blood pressure waveforms based on its unique FDA-cleared and patented SphygmoCor® technology. Under the ATCOR-X brand, the company also develops and licenses its Arty™ platform consisting of physiological and health analytics for wearable devices. The company's digital platform, ArtyNet™, is a connected SaaS ecosystem providing physicians with a complete telehealth solution for remotely managing patients' health (2021 launch).